Educational Objectives

·      Review the efficacy and safety of emerging frontline immune checkpoint inhibitor (ICI) used as monotherapy and in combination regimens

·      Indicate the impact of ICIs and programmed death-ligand 1 testing on cost-effectiveness and patient reported outcomes related with frontline use of ICIs in advanced NSCLC

 

Faculty:

Paul Forsberg, PharmD, MHA, BCOP

Director of Pharmacy

Minnesota Oncology

St. Paul, Minnesota

 

Latha Radhakrishnan, PharmD, BCOP

Clinical Oncology Pharmacist

The University of Illinois Hospital and Health Sciences System

Clinical Assistant Professor

University of Illinois at Chicago College of Pharmacy

Chicago, Illinois

 

Paul Forsberg, PharmD, MHA, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Epizyme

Speakers Bureau: AstraZeneca

 

Latha Radhakrishnan, PharmD, BCOP, has the following relevant financial relationships with commercial interests to disclose:

Consultant: Taiho, Novartis, Exelixis

Speakers Bureau: BMS, AstraZeneca, Taiho, Exelixis

 

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Liza Patel, PharmD, RPh; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta.

Anonymous peer reviewers have been used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 0.5 contact hours (0.05 CEU) under the ACPE universal activity number 0290-0000-22-363-H01-P. The activity is available for CE credit through July 29, 2023.

 

This activity is supported by independent medical education grants from Merck Sharp & Dohme Corp., Regeneron Pharmaceuticals, Inc., and Sanofi Genzyme.

 https://www.pharmacytimes.org/courses/continuing-the-conversation-optimizing-frontline-immunotherapy-outcomes-in-nsclc-and-managed-care-considerations

Learn more about your ad choices. Visit megaphone.fm/adchoices